Colin Love
Founder at REPLIMUNE GROUP, INC.
Net worth: 5 M $ as of 29/04/2024
Colin Love active positions
Companies | Position | Start | End |
---|---|---|---|
REPLIMUNE GROUP, INC. | Chief Operating Officer | 30/09/2015 | - |
Founder | 28/02/2015 | - | |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Director/Board Member | 09/07/2017 | - |
Replimune (Ireland) Ltd.
Replimune (Ireland) Ltd. Miscellaneous Commercial ServicesCommercial Services Replimune (Ireland) Ltd., part of Replimune Group, Inc., is a company headquartered in Dublin, Ireland. The firm provides professional, scientific and technical services. | Director/Board Member | 30/09/2019 | - |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | - | - |
Career history of Colin Love
Former positions of Colin Love
Companies | Position | Start | End |
---|---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 10/03/2021 | 19/02/2024 |
Independent Dir/Board Member | 10/03/2021 | 19/02/2024 | |
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - | 30/07/2015 |
AMGEN INC. | Chief Tech/Sci/R&D Officer | 31/12/2010 | 31/12/2013 |
Corporate Officer/Principal | - | 31/12/2010 | |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Corporate Officer/Principal | 14/10/2009 | 23/01/2013 |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Corporate Officer/Principal | 14/05/2009 | 31/12/2010 |
░░░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Colin Love
University of Glasgow | Doctorate Degree |
Statistics
International
United Kingdom | 7 |
United States | 5 |
Ireland | 2 |
Operational
Corporate Officer/Principal | 5 |
Director/Board Member | 4 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 8 |
Commercial Services | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
REPLIMUNE GROUP, INC. | Health Technology |
AMGEN INC. | Health Technology |
Private companies | 8 |
---|---|
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Commercial Services |
Replimune (Ireland) Ltd.
Replimune (Ireland) Ltd. Miscellaneous Commercial ServicesCommercial Services Replimune (Ireland) Ltd., part of Replimune Group, Inc., is a company headquartered in Dublin, Ireland. The firm provides professional, scientific and technical services. | Commercial Services |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Colin Love
- Experience